Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death

被引:36
|
作者
Ren, H
Nagai, Y
Tucker, T
Strittmatter, WJ
Burke, JR [1 ]
机构
[1] Duke Univ, Med Ctr, Deane Lab, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA
关键词
Huntington's disease; spinocerebellar; ataxia; ataxin; phage display; neurodegeneration; TAT; intracellular delivery; therapy;
D O I
10.1006/bbrc.2001.5783
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteins with expanded polyglutamine domains cause eight inherited neurodegenerative diseases including Huntington's disease. In a previous paper, we identified peptides that inhibit polyglutamine protein aggregation and cell death and now describe the amino acid sequence requirements necessary for these activities. The original 11 amino acid polyglutamine (Q) Binding Peptide I (QBP1; SNWKWWPGIFD) can be shortened to 8 amino acids (WKWWPGIF) without loss of ability to inhibit polyglutamine aggregation. Three determinants are responsible for inhibition: a tryptophan-rich motif (WKWW), a spacer amino acid and the tripeptide GIF. GIF can be replaced by a repeat of the tryptophan-rich motif, but the spacer remains necessary. We also demonstrate concordance between peptide activity in the in vitro assay and a cellular assay of polyglutamine aggregation and cell death. Polyglutamine binding peptides targeted for intracellular delivery by fusion to TAT retain the ability to inhibit polyglutamine aggregation and cell death in transfected COS 7 cells. (C) 2001 Academic Press.
引用
收藏
页码:703 / 710
页数:8
相关论文
共 50 条